Core Insights - Zhengzhou is at a pivotal point between the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan," showcasing significant advancements in various industries over the past five years [1] - The city aims to build a modern industrial system supported by advanced manufacturing, with over 100 billion-level enterprises and several trillion-level industrial clusters by 2025 [4] Industry Developments - The emergence of new industries in Zhengzhou includes sectors such as energy conservation, new generation information technology, biomedicine, high-end equipment manufacturing, new materials, and smart connected vehicles [1] - Zhengzhou has cultivated seven trillion-level industrial clusters, including electronic information and automotive manufacturing, contributing to a stable industrial output value ranking among the top in the country [4][10] Technological Advancements - Yutong Bus has achieved global recognition, winning multiple awards at the World Bus Expo, supported by its core technology and innovations like the "vehicle-battery co-life" technology [5] - The automation rate in BYD's Zhengzhou base has reached over 97%, reflecting the efficiency of smart manufacturing in the production of electric vehicles [6] Manufacturing Excellence - China Railway Engineering Equipment Group has developed world-leading technology for shield machines, exporting to over 30 countries, and emphasizes the importance of digitalization in manufacturing [7] - Zhengzhou's industrial scale has shown consistent growth, with an average annual increase of 9.55% in industrial added value from 2021 to 2024 [10] Future Outlook - Zhengzhou is strategically planning for future industries, focusing on six major directions and laying out 15 new tracks, with the future industry scale exceeding 150 billion [12] - The city aims to drive digital empowerment and transformation towards high-end, intelligent, and green manufacturing, aligning with national strategies and technological advancements [12]

Core Insights - Zhengzhou is transitioning from the "14th Five-Year Plan" to the "15th Five-Year Plan," focusing on high-quality development and modern industrial systems [1][2] - The city aims to establish several trillion-yuan industrial clusters, with a strong emphasis on advanced manufacturing and emerging industries [2][7] Industry Developments - Zhengzhou's industrial landscape features significant players like Yutong in 5G autonomous buses and Hanwei Technology with over 70% market share in gas sensors [2] - The city is home to over 210 million business entities and aims to cultivate seven trillion-yuan industrial clusters, including electronics and automotive manufacturing [2][7] Technological Advancements - Yutong's recent accolades at the World Bus Expo highlight its commitment to innovation, with a focus on electric vehicle technology and automation [3] - The automation rate in BYD's Zhengzhou base has reached over 97%, showcasing advancements in smart manufacturing [3] Digital Transformation - Zhengzhou Coal Machine has rebranded to Zhongchuang Zhiling, emphasizing its shift towards digital and intelligent mining solutions [4] - The establishment of a digital lighthouse factory has significantly improved production efficiency and reduced costs [4] Equipment Manufacturing - China Railway Engineering Equipment Group is leading in shield machine production, with exports to over 30 countries [5] - The company collaborates with Tsinghua University to overcome material challenges, enhancing its competitive edge in the global market [5] Industrial Growth Metrics - Zhengzhou's industrial output has shown a steady annual growth rate of 9.55% from 2021 to 2024, with strategic emerging industries accounting for 50.9% of the industrial value added by 2024 [7][8] - The city has implemented policies to upgrade traditional industries and promote digital transformation, resulting in significant increases in production capacities across various sectors [7][8] Future Outlook - Zhengzhou is positioning itself to leverage national strategies and technological advancements, focusing on a balanced development of traditional, emerging, and future industries [8] - The city plans to expand its future industry scale to over 150 billion yuan, targeting six key directions for growth [8]

证券代码：603658 证券简称：安图生物 公告编号：2025-066 郑州安图生物工程股份有限公司 关于全资子公司完成医疗器械经营许可证及 药品经营许可证变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）全资 子公司郑州安图科技发展有限公司（以下简称"安图科技"）于近日取得郑州经 济技术开发区市场监督管理局换发的《医疗器械经营许可证》以及河南省药品监 督管理局换发的《药品经营许可证》，变更后具体情况如下： 法定代表人：刘军 企业负责人：刘军 住 所：河南自贸试验区郑州片区（经开）经北一路87号院生产研发中心 生产楼 经营场所：河南自贸试验区郑州片区（经开）经北一路87号院生产研发中心 生产楼二楼 库房地址：郑州经济技术开发区经开第十五大街199号12号楼1层B区；武汉 市东西湖区田园大道99号（委托九州通医药集团物流有限公司贮存、配送，仅 限自营产品）；广州市白云区钟落潭镇梅田村康安一街46号仓库楼一层、六层、 八层；中山市火炬开发区沿江东二路11号 ...

Core Viewpoint - Beijing Beier Bioengineering Co., Ltd. has once again paused its IPO journey, marking the third attempt since 2020 without success [2][3] IPO Attempts - Beier Bio's IPO journey has been tumultuous, with multiple attempts since its first application in July 2020, which was withdrawn in February 2021. The company then shifted to the Shanghai Stock Exchange in October 2021, but this attempt also failed. In April 2025, it redirected its efforts to the Beijing Stock Exchange, where its IPO was accepted on June 30, but was halted three months later due to the need for updated financial reports [3][4] Fundraising Plans - The company plans to publicly issue up to 25 million shares, aiming to raise a total of approximately 537 million yuan, which will be allocated to the construction of an in vitro diagnostic reagent and instrument production base and a research and development center [4][5] Project Feasibility Concerns - Despite claiming to be a "national-level specialized and innovative small giant," the feasibility and return prospects of its fundraising projects are questioned due to tightening industry policies, increasing market competition, and rising tax burdens [4][6] Financial Performance - Beier Bio has experienced significant revenue fluctuations, with a 50.57% increase in revenue and a 237.21% increase in net profit in 2023, followed by a decline in both metrics in 2024, with revenue down 9.08% and net profit down 6.00% [7][8] Core Product Revenue Decline - The decline in revenue is primarily attributed to a drop in income from core product lines, particularly the respiratory pathogen detection series, which saw a 10.3% decrease in revenue from 2023 to 2024 [9][10] Market Competition and Risks - The in vitro diagnostic market is highly competitive, with major players like Roche and Abbott dominating. Beier Bio's lack of brand influence and market coverage raises concerns about its ability to maintain market share if competitors adopt aggressive pricing strategies [6][11] Tax Policy Impact - Starting in 2025, the company will face increased tax burdens as it transitions from a simplified tax method to a general tax method, significantly raising its tax costs and further squeezing profit margins [6][11] Technology Transition Challenges - The company heavily relies on traditional enzyme-linked immunosorbent assays and colloidal gold reagents, which are losing market share to newer technologies like chemiluminescence. If Beier Bio fails to adapt and innovate, it risks being outpaced by competitors [10][11]

Core Viewpoint - The announcement highlights that Zhengzhou Antu Biological Engineering Co., Ltd. and its wholly-owned subsidiary, Antu Instrument (Zhengzhou) Co., Ltd., have received medical device registration certificates from the National Medical Products Administration, which enhances the company's product offerings and competitiveness in the market [1][2]. Group 1: Medical Device Registration - The company and its subsidiary have recently obtained medical device registration certificates, which are crucial for expanding their product portfolio [1]. - The registration certificates were issued by the National Medical Products Administration and the Henan Provincial Drug Administration [1]. Group 2: Market Impact - The acquisition of the medical device registration certificates will enrich the company's product menu and meet market demands, serving as an effective supplement to existing detection products [2]. - The short-term impact on the company's operating performance is expected to be minimal [2]. Group 3: Industry Context - Similar products have been registered by various domestic and international manufacturers, indicating a competitive landscape in the medical device sector [1].

Core Viewpoint - Antu Biology (603658.SH) has received medical device registration certificates from the National Medical Products Administration and the Henan Provincial Drug Administration, enhancing its product offerings and competitiveness in the market [1] Group 1 - The acquisition of the medical device registration certificates enriches the company's product menu [1] - The new certifications serve as an effective supplement to the company's existing testing products [1] - The short-term impact on the company's operating performance is expected to be minimal [1]

Core Viewpoint - Antu Biology (603658.SH) has received medical device registration certificates from the National Medical Products Administration and the Henan Provincial Drug Administration, enhancing its product offerings and competitiveness in the market [1] Group 1 - The company and its wholly-owned subsidiary, Antu Instrument (Zhengzhou) Co., Ltd., have recently obtained medical device registration certificates [1] - The acquisition of these certificates enriches the company's product menu and meets market demand [1] - This development serves as an effective supplement to the company's existing testing products, gradually improving overall competitiveness [1] Group 2 - The short-term impact on the company's operating performance is expected to be minimal [1]

二、同类产品相关情况 证券代码：603658 证券简称：安图生物 公告编号：2025-065 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及全 资子公司安图实验仪器（郑州）有限公司（以下简称"安图仪器"）于近日收到 国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | 所属 | | --- | --- | --- | --- | --- | --- | | | | | 有效期 | | 公司 | | 1 | 曲霉菌半乳甘露聚糖 抗原检测试剂盒（磁 微粒化学发光法） | 国械注准 20253401899 | 年 5 | 本产品用于体外定性检测人血清中的 曲霉菌半乳甘露聚糖抗原（GM）。 | | | 2 | 曲霉菌 抗体检测 IgG 试剂盒（磁微粒化学 发光法） | 国械注准 20253402004 | ...

Summary of Key Points from the Conference Call on the Medical Device Industry Industry Overview - The Chinese medical device industry has significant potential for domestic substitution, with certain segments still having room for improvement in localization rates [1][3][10] - Chinese companies are positioned to become global leaders in the context of globalization, leveraging strong innovation capabilities and manufacturing advantages [1][4][10] Core Insights and Arguments - The high-value consumables sector is expected to see a notable recovery by 2025, with investment opportunities in orthopedics, neurointervention, ophthalmology, and electrophysiology [1][5] - Companies such as Huatai Medical, MicroPort, Lepu Medical, Mindray, and United Imaging are highlighted for their growth potential [1][5] - The upstream medical device sector is experiencing a turning point, with companies like Meihua Medical and Yirui Technology poised for significant revenue growth due to innovative products [1][6] - The in vitro diagnostics (IVD) sector has faced challenges due to policy impacts, but a recovery is anticipated next year, with New Industry expected to see positive revenue growth in Q4 [1][7] - Strategic adjustments by Chinese medical device companies include cost reduction, technological innovation, transformation to consumer-oriented businesses, and overseas market expansion [1][9] Additional Important Insights - The global medical device market is approximately 4 to 5 times larger than China's market, which is projected to grow significantly [2][12] - Chinese companies are diversifying their overseas expansion strategies, which include R&D innovation, clinical registration, and patent layout to mitigate geopolitical risks [2][11][14] - The importance of innovation is emphasized as a key driver for growth, with a focus on new product development and emerging technologies such as AI and brain-computer interfaces [26][31] - The medical device industry is witnessing a trend towards mergers and acquisitions as a means for companies to enhance their product lines and market positions [33][36] Notable Companies and Their Strategies - Mindray Medical is leading in internationalization, with overseas revenue expected to reach 45% in 2024 [19] - United Imaging and BGI are also making significant strides in their respective markets, with notable growth in overseas business [19][24] - High-value consumables companies like Nanwei Medical and MicroPort are employing various strategies, including direct sales and ODM, to expand their international presence [21][22] Future Outlook - The medical device industry is expected to continue evolving, with significant opportunities in areas such as AI healthcare applications, home respiratory devices, and surgical robots [28][30] - The brain-computer interface technology is emerging as a key investment area, with China positioned as a global leader [31] - The overall sentiment is optimistic regarding the recovery and growth potential of the Chinese medical device market, particularly as companies adapt to changing market conditions and consumer demands [36]

基本情况 | 投资金额 | 万元 17,000 | | --- | --- | | 投资种类 | 大额存单 | | 资金来源 | 募集资金 | 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603658 证券简称：安图生物 公告编号：2025-064 已履行的审议程序 郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会议，审议 通过《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在 确保不影响募集资金投资项目建设和募集资金使用的情况下，公司拟分 别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收 益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额 度范围内，资金可在 ...